RNA-seq profiling of A375 melanoma cells treated with Salvianolic Acid B

This dataset describes the transcriptomic profiling of A375 human melanoma cells treated with Salvianolic Acid B (Sal B), a bioactive compound derived from Salvia miltiorrhiza. A375 cells were cultured under standard conditions and treated with Sal B at concentrations of 100 µM and 200 µM for 48 hours, with an untreated control group included for comparison. Total RNA was extracted from each group and subjected to RNA-seq analysis to investigate global gene expression changes induced by Sal B. The goal of this study was to identify differentially expressed genes and pathways related to glycolysis inhibition and immune modulation, providing insight into the potential anti-tumor mechanisms of Sal B in melanoma. This dataset may serve as a resource for exploring the metabolic and immunological effects of Salvianolic Acid B in melanoma cells. Overall design: A total of nine samples were collected from A375 human melanoma cells divided into three groups: untreated control (Con), Salvianolic Acid B low-dose treatment (SalB 100 µM), and high-dose treatment (SalB 200 µM). Each group included three biological replicates. Cells were treated for 48 hours under standard culture conditions (37°C, 5% CO2). Total RNA was extracted using TRIzol reagent, and RNA quality was verified by Bioanalyzer. Libraries were prepared using a standard mRNA-seq protocol and sequenced on an Illumina platform to generate paired-end reads.